Trastuzumab is a human epidermal growth factor receptor 2 inhibitor used for the management of human epidermal growth factor receptor 2–positive breast cancer or human epidermal growth factor receptor 2–overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. This evidence concerns the gene ERBB2 and gastroesophageal junction adenocarcinoma.